COMPANY

Quanta Therapeutics

HQ: South San Francisco, CA source · quantatx.com ↗ · West Coast

Quanta Therapeutics is a South San Francisco, CA biotech developing oral small-molecule KRAS inhibitors for cancer. From company website Source · Oct 12, 2026

Keywords: small molecule oncology KRAS South San Francisco, CA QTX3034 QTX3544 QTX3046

Profile checked Oct 10, 2026

3Trials (company is sponsor)

Timeline

Jan 14, 2025 Trial start Phase 1: QTX3544 in Patients With Advanced Solid Tumors With KRAS G12V Mutations source ↗
May 30, 2024 Trial start Phase 1: QTX3046 in Patients With KRAS G12D Mutations source ↗
Feb 5, 2024 Trial start Phase 1: QTX3034 in Patients With KRAS G12D Mutation source ↗

Upcoming milestones

Jan 2, 2027 (ESTIMATED) · Phase 1 · QTX3544 in Patients With Advanced Solid Tumors With KRAS G12V Mutations · NCT06715124
Apr 1, 2027 (ESTIMATED) · Phase 1 · QTX3034 in Patients With KRAS G12D Mutation · NCT06227377
Jul 1, 2027 (ESTIMATED) · Phase 1 · QTX3046 in Patients With KRAS G12D Mutations · NCT06428500

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 3

Record	Title	Phase	Status	Start	Primary completion
NCT06227377	QTX3034 in Patients With KRAS G12D Mutation	Phase 1	Recruiting	Feb 5, 2024	Apr 1, 2027 (estimated)
NCT06715124	QTX3544 in Patients With Advanced Solid Tumors With KRAS G12V Mutations	Phase 1	Active, not recruiting	Jan 14, 2025	Jan 2, 2027 (estimated)
NCT06428500	QTX3046 in Patients With KRAS G12D Mutations	Phase 1	Active, not recruiting	May 30, 2024	Jul 1, 2027 (estimated)